FDA Grants Fast Track Designation to SonALAsense’s SONALA-001 in Combination with the INSIGHTEC Transcranial Ultrasound Device for Sonodynamic Therapy of DIPG, a Rare Pediatric Brain Cancer
November 14, 2023
Encouraging preliminary data from the ongoing DIPG clinical study to be presented at the 2023 Society for Neuro-Oncology Annual Meeting in Vancouver
View Video: Our Director of Patient Advocacy moderated an insightful panel discussion at the White House Cancer Moonshot Brain Cancers Forum on GBM & DIPG on May 25, 2023
May 25, 2023
April Freeman Brings Her Personal and Professional Experience to SonALAsense as Patient Advocate
July 28, 2022
April recently joined SonALAsense as Director of Patient Advocacy and Engagement, helping build alliances with patient and trade organizations / associations to raise awareness of, and educate on, sonodynamic therapy and recruit patients for recurrent glioblastoma (GBM) and diffuse intrinsic pontine glioma (DIPG) clinical trials.
SonALAsense Achieves Significant Clinical, Growth and Funding Milestones Toward its Mission to Soundly Defeat Cancer
June 28, 2022
Company has received Safe to Proceed letters from FDA for two clinical trials in life-threatening brain tumors, DIPG trial is open and actively recruiting, it has expanded its executive leadership team and scientific advisory board and completed a Series B funding round.
SonALAsense Q&A with Dr. Scott Plotkin
June 21, 2022
Dr. Scott Plotkin, MD, PhD is the Executive Director at the Pappas Center for Neuro-Oncology at Massachusetts General Hospital and the Giovanni Armenise– Harvard Professor of Neurology at Harvard Medical School. He completed his neurology training at Mass General Brigham and Women's Hospital in Boston in 2002, and then trained in neuro-oncology at Mass General Hospital the following year. He has been on the faculty ever since and now also sits on the Scientific Advisory Board for SonALAsense.
